Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.60 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.60 |
| ▸ | BRS3 | P32247 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.60 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.60 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.60 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.60 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.60 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.60 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.60 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.60 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.60 |
| ▸ | WDR5 | P61964 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.60 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omeprazole SCHEMBL1192 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29772327 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL19535 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL30426884 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29360040 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL28256108 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL29691369 | 1.00 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2867502 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2517856 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL265327 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 713 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114514030-B | Microbiome intervention | 马斯公司 | 2025-02-11 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-115504962-A | Benzimidazole derivatives for the treatment and/or prevention of diseases and disorders mediated by NLRP3 | 思捷优达股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-109066699-B | Method for judging influence of overmodulation on micro-source inverter series micro-grid voltage | 兰州理工大学 | 2021-11-02 | — | — | CN | claimed |
| CN-107046288-B | Structure of hybrid harmonic suppressor and control method thereof | 广东工业大学 | 2020-10-16 | — | — | CN | claimed |
| EP-3031451-B1 | WET GRANULATION TABLETING METHOD USING AQUEOUS DISPERSION OF LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | SHINETSU CHEMICAL CO (JP) | 2018-03-07 | — | — | EP | claimed |
| CN-104606146-B | A kind of esomeprazole enteric capsules preparation and preparation method thereof | 苏州大学 | 2017-12-19 | — | — | CN | claimed |
| CN-104546842-B | A kind of omeprazole composition and preparation method thereof | 辰欣药业股份有限公司 | 2017-08-04 | — | — | CN | claimed |
| CN-106632256-A | Synthesis method of proton pump inhibitors | 河南师范大学 | 2017-05-10 | — | — | CN | claimed |
| US-5389664-A | Administering benzimidazole compounds to inhibit at pase activity | MONSANTO COMPANY (US) | 1995-02-14 | — | — | US | claimed |
| EP-0423748-B1 | Stabilized pharmaceutical composition and its production | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-08-24 | — | — | EP | claimed |
| EP-0237200-B1 | USE OF BASIC INORGANIC SALTS OF MAGNESIUM OR CALCIUM FOR THE STABILISATION OF BENZIMIDAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1992-07-01 | — | — | EP | claimed |
| EP-0446961-A2 | Stabilized pharmaceutical composition and its production | Takeda Chemical Industries, Ltd. (JP) | 1991-09-18 | — | — | EP | claimed |
| US-5045321-A | Antiulcer compound lansoprazole or omeprazole with magnesium and/or calcium salt; tablets or granules | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-03 | — | — | US | claimed |
| US-5013743-A | Use of substituted pyridylmethylsulfinyl- and pyridylmethylthiobenzimidazoles such as lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl)methylthiobenzimidazole | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-07 | — | — | US | claimed |
| EP-0423748-A1 | Stabilized pharmaceutical composition and its production | Takeda Chemical Industries, Ltd. (JP) | 1991-04-24 | — | — | EP | claimed |
| EP-0382489-A2 | Use of benzimidazole derivatives as antibacterial agents | Takeda Chemical Industries, Ltd. (JP) | 1990-08-16 | — | — | EP | claimed |
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | claimed |
| EP-0237200-A2 | Use of basic inorganic salts of magnesium or calcium for the stabilisation of benzimidazole derivatives | Takeda Chemical Industries, Ltd. (JP) | 1987-09-16 | — | — | EP | claimed |